HER2CLIMB

NCT02614794 📎

Regimen

Experimental
Tucatinib 300 mg PO BID + trastuzumab + capecitabine.
Control
Placebo + trastuzumab + capecitabine.

Population

HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab and T-DM1; approximately 48% had brain metastases (including active/progressing).

Key finding

HER2CLIMB established tucatinib + trastuzumab + capecitabine as the standard CNS-active regimen for pretreated HER2+ MBC with brain metastases (NCCN preferred). Landmark: first trial to enroll patients with active, untreated brain metastases.

Source: PMID 31825569

Timeline

  • Publication: 2020 Feb 13

Guideline citations

  • NCCN BREAST